跳至主要内容
临床试验/DRKS00013220
DRKS00013220进行中(未招募)不适用

Role of bowel ultrasonography to guide treatment with vedolizumab in patients with Crohn's disease and ulcerative colitis - VedoSono

Takeda Pharma Vertrieb GmbH & Co KG0 个研究点目标入组 65 人开始时间: 2018年3月20日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
65

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 70 Years(—)
性别
All

入选标准

  • Inclusion criteria for patients with active disease (study part 1):
  • 1. Reliable diagnosis of Crohn's disease (active disease):
  • a. HBI = 7 and
  • b. Sonographic signs of active inflammation: intestinal wall thickness> 3.0 mm (colon) or> 2.0 mm (terminal ileum)
  • Reliable diagnosis of ulcerative colitis (active disease):
  • a. SCCAI = 5 and
  • b. Sonographic signs of active inflammation:
  • Intestinal wall thickness> 3.0 mm (Colon)
  • 2. Study-independent therapy with vedolizumab
  • according to medical practice
  • 3. Age 18 to 70 years
  • 4. Sufficient communication skills in the German language
  • 5. Patient must be able to recognize the nature, significance and scope of this study and to orientate its will accordingly
  • Inclusion criteria for patients in remission (study part 2):
  • 1. Reliable diagnosis of Crohn's disease (remission): HBI = 4
  • Reliable diagnosis of ulcerative colitis (remission):
  • 2. Study-independent therapy with vedolizumab
  • according to medical practice
  • 3. Age 18 to 70 years
  • 4. Sufficient communication skills in the German language
  • 5. Patient must be able to recognize the nature, significance and scope of this study and to orientate its will accordingly

排除标准

  • 1. Pregnancy or breastfeeding
  • 2. Therapy with vedolizumab out of authorization
  • 3. Contraindication to treatment with vedolizumab (sec.reg. FI)
  • 4. Severe symptomatic strictures without signs of blood flow
  • 5. Ileostoma or ileoanal pouch
  • 6. Infectious colitis (e.g., Clostridium difficile colitis,
  • Cytomegalovirus colitis)
  • 7. Obesity = grade I (BMI> 30) (insufficient, sonographic bowel wall imaging)
  • 8. Ulcerative colitis: proctitis Crohn's disease: infestation of the upper GI tract (esophagus, stomach)
  • 9. Participation in an intervention study within the last 30 days prior to initiation of therapy
  • 10. Other medical reasons

研究者

相似试验